.Nature Medication, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research, after a mean consequence of 11 months, clients along with metastatic intestinal growths that received biomarker-matched therapies based on distributing cyst DNA profiling revealed a greater professional advantage than those obtaining unparalleled therapy.